Tandem Diabetes Reports Mixed Q4 Earnings, Issues Better Than Expected FY22 Outlook

Tandem Diabetes Care Inc TNDM reported Q4 sales reached $209.9 million, +25% Y/Y, beating the consensus of $199.12 million.

• The Company posted EPS of $0.16, down from $0.22 a year ago, and missed the Wall Street estimate of $0.21.
• Worldwide pump shipments increased 15% Y/Y to 37,585.
• The gross margin remained almost unchanged at 54%, and the operating margin decreased from 11% to 6%.
• Tandem Diabetes ended Q3 with cash, cash equivalents, and short-term investments of $595.0 million.
• Guidance: Tandem forecasts FY22 sales of $845 million - $860 million, representing a Y/Y growth of 20% - 22%, beating the consensus of $827.23 million.
• The guidance includes sales outside the U.S. of approximately $215 million to $220 million.
• The gross margin is estimated to be around 54%, with an adjusted EBITDA margin of 14% - 15%.
• Price Action: TNDM shares traded 2% lower at $104.03 during the market session on the last check Wednesday.